Mark McManish, M.D., Ph.D

President and CEO of IconOVir Bio

Dr. McCamish is President and Chief Executive Officer of IconOVir Bio. Prior to his leadership at InconOVir, McCamish was President and CEO of Forty Seven, Inc during crucial phases of clinical development to help patients beat their cancer. This included growing Forty Seven Inc. from a $169 million valuation as a private company to a final acquisition of the company by Gilead Sciences for $4.9 Billion.

He is a world-renowned expert in biologic development and manufacturing. Mark is a senior executive with a wealth of experience at various pharmaceutical companies including Abbott, Amgen, and Novartis. He led pioneering efforts in launching biosimilars internationally. He exhibits a business-oriented mindset in establishing research and development strategies leading to commercial success in many and varied treatment areas.

He received Bachelor’s and Master’s degrees from The University of California, Santa Barbara, his PhD in Human Nutrition from Penn State and MD from UCLA, then completed his Residency and Fellowship Training at the University of California, Davis.